- Home
- PLUR vs PHGE Comparison
PLUR vs PHGE Comparison
Compare PLUR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- PHGE
- Stock Information
- Founded
- PLUR 2001
- PHGE 2015
- Country
- PLUR Israel
- PHGE Israel
- Employees
- PLUR N/A
- PHGE N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- PHGE Health Care
- Exchange
- PLUR Nasdaq
- PHGE Nasdaq
- Market Cap
- PLUR 30.2M
- PHGE 26.5M
- IPO Year
- PLUR N/A
- PHGE N/A
- Fundamental
- Price
- PLUR $4.81
- PHGE $0.95
- Analyst Decision
- PLUR
- PHGE Strong Buy
- Analyst Count
- PLUR 0
- PHGE 2
- Target Price
- PLUR N/A
- PHGE $22.50
- AVG Volume (30 Days)
- PLUR 16.4K
- PHGE 35.5K
- Earning Date
- PLUR 11-11-2024
- PHGE 11-12-2024
- Dividend Yield
- PLUR N/A
- PHGE N/A
- EPS Growth
- PLUR N/A
- PHGE N/A
- EPS
- PLUR N/A
- PHGE N/A
- Revenue
- PLUR $326,000.00
- PHGE N/A
- Revenue This Year
- PLUR N/A
- PHGE N/A
- Revenue Next Year
- PLUR N/A
- PHGE N/A
- P/E Ratio
- PLUR N/A
- PHGE N/A
- Revenue Growth
- PLUR 13.59
- PHGE N/A
- 52 Week Low
- PLUR $3.44
- PHGE $0.88
- 52 Week High
- PLUR $8.48
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- PLUR 42.15
- PHGE 38.91
- Support Level
- PLUR $4.52
- PHGE $0.92
- Resistance Level
- PLUR $5.34
- PHGE $0.99
- Average True Range (ATR)
- PLUR 0.40
- PHGE 0.06
- MACD
- PLUR -0.06
- PHGE 0.02
- Stochastic Oscillator
- PLUR 17.40
- PHGE 32.64
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.